Page 119 - 《中国药房》2024年4期
P. 119

(9):59-61.                                          异常的影响因素分析[J]. 药物流行病学杂志,2019,28
              DAI X Q,MA C X,CAI Y,et al. Analysis of risk factors   (9):578-580,590.
              of  coagulation  dysfunction  caused  by  cefoperazone  sodium   SHI S P,WU X,NONG J C,et al. Influencing factors of
              and  sulbactam  sodium  and  nursing  care  of  them[J].  J   coagulation  abnormalities  induced  by  cefoperazone/sul‐
              Nurs,2013,20(9):59-61.                              bactam[J]. Chin J Pharmacoepidemiol,2019,28(9):578-
          [13]  朱愿超,梁良,沈姞,等. 头孢哌酮钠舒巴坦钠致凝血功                        580,590.
              能异常的临床特征和相关因素分析[J]. 中国药学杂志,                    [18]  谭皓文. Logistic回归分析联合ROC曲线对头孢哌酮-舒
              2022,57(9):741-746.                                 巴坦钠致凝血功能异常的预测分析[J]. 抗感染药学,
              ZHU Y C,LIANG L,SHEN J,et al. Clinical features and   2022,19(2):300-304.
              risk  factors  of  coagulation  disorders  caused  by  cefopera‐  TAN H W. Prediction of coagulation disorders caused by
              zone  sodium  and  sulbactam  sodium[J].  Chin  Pharm  J,  cefoperazone/sulbactam  with  logistic  regression  analysis
              2022,57(9):741-746.                                 combined with ROC curve[J]. Anti Infect Pharm,2022,19
          [14]  杜佳丽,焦红梅,孙丹,等. 头孢哌酮/舒巴坦致老年患者                      (2):300-304.
              凝血功能异常的相关因素分析[J]. 中国临床药理学杂                     [19]  周华,李光辉,陈佰义,等. 中国产超广谱β-内酰胺酶肠
              志,2016,32(24):2303-2306.                            杆菌科细菌感染应对策略专家共识[J]. 中华医学杂志,
              DU J L,JIAO H M,SUN D,et al. Analysis of relative fac‐  2014,94(24):1847-1856.
              tors  for  coagulation  abnormalities  induced  by  cefopera‐  ZHOU H,LI G H,CHEN B Y,et al. Expert consensus on
              zone/sulbactam in elderly patients[J]. Chin J Clin Pharma‐  coping strategies of extended-spectrum β-lactamases pro‐
              col,2016,32(24):2303-2306.                          ducing Enterobacteriaceae infection in China[J]. Natl Med
          [15]  梁河,蒙光义,钟丽球,等. 头孢哌酮钠舒巴坦钠致缺血                        J China,2014,94(24):1847-1856.
              性脑血管病患者凝血功能异常的影响因素分析[J]. 中国                    [20]  中国医药教育协会感染疾病专业委员会. 抗菌药物药代
              药物警戒,2022,19(1):87-90.                              动力学/药效学理论临床应用专家共识[J]. 中华结核和
              LIANG H,MENG G Y,ZHONG L Q,et al. Influencing       呼吸杂志,2018,41(6):409-446.
              factors of coagulation abnormalities induced by cefopera‐  Chinese Medical Education Association Professional Com‐
              zone  sodium  and  sulbactam  sodium  in  patients  with  is-  mittee of Infection Diseases. Expert consensus on clinical
              chemic cerebrovascular disease[J]. Chin J Pharmacovigil,  application  of  pharmacokinetic/pharmacodynamic  theory
              2022,19(1):87-90.                                   of antibacterial drugs[J]. Chin J Tuberc Respir Dis,2018,
          [16]  王钰莹,于建海,段京莉. 头孢哌酮舒巴坦引起凝血功能                        41(6):409-446.
              异常的影响因素分析研究[J]. 中国全科医学,2020,23                 [21]  CHEN  L  J,HSIAO  F  Y,SHEN  L  J,et  al.  Use  of
              (增刊1):138-140.                                      hypoprothrombinemia-inducing  cephalosporins  and  the
              WANG Y Y,YU J H,DUAN J L. Analysis of influencing   risk  of  hemorrhagic  events:a  nationwide  nested  case-
              factors of coagulation dysfunction caused by cefoperazone   control study[J]. PLoS One,2016,11(7):e0158407.
              and  sulbactam[J].  Chin  Gen  Pract,2020,23(Suppl  1):       (收稿日期:2023-05-20  修回日期:2024-01-18)
              138-140.                                                                            (编辑:陈 宏)
          [17]  石姗平,吴雪,农杰昌,等. 头孢哌酮/舒巴坦致凝血功能
























          中国药房  2024年第35卷第4期                                                 China Pharmacy  2024 Vol. 35  No. 4    · 493 ·
   114   115   116   117   118   119   120   121   122   123   124